Genfit S.A.

Genfit S.A.verified

GNFT

Price:

$3.67

Market Cap:

$173.53M

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic ...[Read more]

Industry

Biotechnology

IPO Date

2019-03-27

Stock Exchange

NASDAQ

Ticker

GNFT

The ROE as of December 2024 (TTM) for Genfit S.A. (GNFT) is 1.77%

According to Genfit S.A.’s latest financial reports and current stock price. The company's current ROE is 1.77%. This represents a change of -181.64% compared to the average of -2.17% of the last 4 quarters.

Genfit S.A. (GNFT) Historical ROE (quarterly & annually)

How has GNFT ROE performed in the past?

The mean historical ROE of Genfit S.A. over the last ten years is 2.30%. The current 1.77% ROE has changed -22.88% with respect to the historical average. Over the past ten years (40 quarters), GNFT's ROE was at its highest in in the December 2020 quarter at 298.29%. The ROE was at its lowest in in the December 2018 quarter at -204.62%.

Quarterly (TTM)
Annual

Average

2.30%

Median

-28.01%

Minimum

-379.77%

Maximum

626.29%

Genfit S.A. (GNFT) ROE by Quarter and Year

Discovering the peaks and valleys of Genfit S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 575.44%

Maximum Annual ROE = 626.29%

Minimum Annual Increase = -908.18%

Minimum Annual ROE = -379.77%

Quarterly (TTM)
Annual
YearROEChange
2023-42.52%69.46%
2022-25.09%-144.43%
202156.47%-90.98%
2020626.29%-908.18%
2019-77.49%-79.59%
2018-379.77%575.44%
2017-56.23%138.48%
2016-23.58%-23.75%
2015-30.92%27.91%
2014-24.17%-73.07%

Genfit S.A. (GNFT) Average ROE

How has GNFT ROE performed in the past?

The current ROE of Genfit S.A. (GNFT) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-3.71%

5-year avg

107.53%

10-year avg

2.30%

Genfit S.A. (GNFT) ROE vs. Peers

How is GNFT’s ROE compared to its peers?

Genfit S.A.’s ROE is greater than Cyteir Therapeutics, Inc. (-9.44%), greater than ERYTECH Pharma S.A. (-84.88%), less than Eliem Therapeutics, Inc. (0%), greater than HCW Biologics Inc. (-2516.87%), greater than Molecular Partners AG (-39.16%), greater than MediciNova, Inc. (-20.70%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Champions Oncology, Inc. (66.22%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Janux Therapeutics, Inc. (-10.46%), less than Fennec Pharmaceuticals Inc. (31.99%), greater than Edgewise Therapeutics, Inc. (-26.83%), less than Harmony Biosciences Holdings, Inc. (23.16%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Adagene Inc. (-50.10%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.95%), greater than Rezolute, Inc. (-69.83%), greater than AN2 Therapeutics, Inc. (-57.63%),

Build a custom stock screener for Genfit S.A. (GNFT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Genfit S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Genfit S.A. (GNFT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Genfit S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Genfit S.A.'s ROE?

How is the ROE calculated for Genfit S.A. (GNFT)?

What is the highest ROE for Genfit S.A. (GNFT)?

What is the 3-year average ROE for Genfit S.A. (GNFT)?

What is the 5-year average ROE for Genfit S.A. (GNFT)?

How does the current ROE for Genfit S.A. (GNFT) compare to its historical average?